Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Malin BerlingMohammad A ChaudharyYong YuanNebibe VarolPeter DaleEleonora TestaJohan KlintAdam LeeSolomon J LubingaJohn R PenrodPublished in: Journal of medical economics (2022)
NIVO + IPI was estimated to be cost-effective as a first-line treatment for stage IV or recurrent NSCLC in the US, with increased survival and higher cost compared with PDC.